Figure 3 | British Journal of Cancer

Figure 3

From: Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

Figure 3

(A) Representative Ktrans maps of PaCa13 tumours after treatment with vehicle control (0.9% saline), maximum tolerated dose gemcitabine (MTD Gem; 240 mg kg−1 on days 1, 8, and 15), or metronomic gemcitabine (30 mg kg−1, q3d) for 4 weeks. (B) Effects of different treatments on median values of Ktrans in viable tumour tissues in PaCa8 and PaCa13 tumours. Each symbol represents an evaluable tumour from a mouse in the corresponding group. —, mean; bars, s.e. *P<0.05, significantly different from that of vehicle control. #P<0.05, significantly different from that of MTD gemcitabine.

Back to article page